Expert Interviews

Inside Cardiology: Lipid Management in 2021

April 05, 2021

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Improving Patient Outcomes, Balancing Cost of Mobile Stroke Units with Louise McCullough, MD, PhD

March 23, 2021

Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.

Gregory Weiss, MD: Heart Failure Management in 2020

January 05, 2021

Gregory Weiss, MD, offers perspective on the diagnosis and management of heart failure during 2020.

Year in Review: Clinical Trials in Cardiology During COVID-19

January 01, 2021

Deepak Bhatt, MD, MPH, offers his perspective on how the ongoing pandemic has influenced clinical trials during 2020 and whether he thinks any changes will persist beyond the COVID-19 era.

Year in Review: Advances in Lipid Management During 2020

December 28, 2020

Practical Cardiology Advisory Board Member Brett Nowlan, MD, offers his perspective on the most important advances and topics in the field of lipidology from 2020.

The Importance of Educating Patients on Fish Oil Supplements vs Icosapent Ethyl

December 17, 2020

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

November 21, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

John McMurray, MD: DAPA-CKD and Cardiorenal Protection

November 14, 2020

Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.